Since the loss of PTEN, a negative regulator of the PI3K pathway, occurs in 40% to 50% of patients with PCa and results in PI3K hyperactivation [12,13], there have been significant efforts to identify PI3K inhibitors that can improve efficacy [11,14,15,16]. This evidence concerns the gene PTEN and posterior cortical atrophy.